Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

NCT00110149 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Company withdrew drug supply

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

Beth Israel Deaconess Medical Center